Global Partners L.P. (GLP)
NYSE NYSE Primary 
Why People are Drinking Less & GLP-1 Drug Impact on Alcohol Consumption
Marten Lodewijks, managing director and president of IWSR, breaks down what's behind the decline in global alcohol consumption. He discusses how emerging markets are impacting overall consumption trends, misconceptions about Gen Z's role in the decline, and the boom of ready-to-drink cocktails.
The GLP-1 stock nobody is pricing in isn't a drugmaker
Scott Galloway and Ed Elson laid out the math on Prof G Markets and it should make every fast food shareholder uneasy: roughly 30 million Americans, about 1 in 8 US adults, are now on GLP-1s, and the drugs are reducing fast food's addressable market by an estimated 27-30%.
Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases
Some employers are planning to drop coverage of GLP-1 drugs for weight loss next year as more people take the medications, counteracting some savings from lower prices for Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo.
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
Gen Z and GLP-1 drugs to power Gym Group's growth, says analyst
The Gym Group PLC (LSE:GYM) remains one of Deutsche Bank's preferred stocks in the leisure sector, with the broker arguing that powerful demographic and health trends continue to support long-term growth. Analyst Tim Barrett reiterated a 'buy' recommendation and a 230p target price on the budget gym operator, compared with Tuesday's closing price of 207p.
Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying
More employers and health plans are balking at paying for costly GLP-1 drugs like Ozempic, Zepbound and Wegovy for weight loss and the treatment of obesity, according to a new report.
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
Novo Nordisk and Eli Lilly are introducing GLP-1 pills for obesity, and that competition was on display this weekend at the American Diabetes Association (ADA) Scientific Sessions. CNBC spoke to Novo Nordisk CEO Mike Doustdar and Eli Lilly & Co. CEO Dave Ricks at ADA.
The Wegovy pill is still dominating the GLP-1 pill market
It has remained a top choice among Americans trying to lose weight even after the launch of Foundayo, Eli Lilly's GLP-1 pill.
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s?
LLY's 2026 deal-making spree spans vaccines, oncology and neuroscience, aiming to diversify growth beyond GLP-1s amid rising obesity competition.
Should Value Investors Buy Global Partners (GLP) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wegovy pill maintains GLP-1 lead over Lilly rival, but weekly growth slows
Novo Nordisk's (NYSE:NVO) oral GLP-1 weight-loss drug Wegovy pill continues to outsell Eli Lilly's recently launched competing tablet, but weekly prescription growth is slowing as the market absorbs a new entrant, according to the latest tracking data. GLP-1, or glucagon-like peptide-1, refers to a class of drugs that mimic a gut hormone to suppress appetite and regulate blood sugar, and has become the most hotly contested space in global pharmaceuticals.
Lilly's Mounjaro tops other GLP-1s for some type 2 diabetes patients
We also report on two studies with findings that could bring eventual relief for patients still struggling with long COVID symptoms.
